Ropinirole Drugs, Importers, Informations, User, warnings, Reviews, Side, Effects, Molecular Formula C16H24N2O, Molecular Weight 260.37, CAS Registry Number 91374-21-9, Symptoms, Raw Material Exporters, Details, Drug Effectiveness, Ropinirole, fda, Information of Diseases, Drug, Details, Emergency, Interactions, api, Active Pharmaceutical Ingredients, Dosage, Taj Pharmaceuticals LTd.

Sitemap | Contact Us

Welcome To Taj Pharmaceuticals Ltd API

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved

Ropinirole Taj Pharmaceuticals Ltd.

India

Latin America/ Caribbean

Africa & Middle East

Asia

Russia

Europe

Ropinirole Manufacturers in India Suppliers Ropinirole Exporters Distributors Ropinirole api active pharmaceuticals ingredients Ropinirole manufacturers Side Effects bulk drugs raw material Ropinirole companies Side Effects Importers Ropinirole Ropinirole Exporters Ropinirole exporters FDA Ropinirole DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Ropinirole manufacturing pharmaceutical drugs pharmaceutical intermediates Ropinirole pharmaceutical chemicals pharmaceutical raw materials Ropinirole active pharmaceutical ingredients Ropinirole committee active pharmaceutical ingredients manufacturer Ropinirole Active Pharmaceutical Ingredients manufacturer Ropinirole exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Ropinirole, Ropinirole manufacturer India, Ropinirole product, Ropinirole products, Api preparation, Certificate of Analysis API manufacturer product, Ropinirole anti ulcer product, Certificate of Origin COA Ropinirole COS Ropinirole, pharmaceutical generic, pharmaceutical drug, medical, Ropinirole pharma healthcare, pharma patents, contract MSDS manufacturing Trader Ropinirole pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Ropinirole expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Ropinirole DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Ropinirole ingredients, api, HIV Ropinirole, tablets, capsules, syrup & protein Ropinirole powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Ropinirole gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Ropinirole WHO, UKMHRA Approval

	PRODUCT LIST
	Home
	API >>>
	Pharmaceuticals API List
	Chemicals
	Manufacturing
	Product Development
	Product Search
	Agro Chemicals
	Custom Pharma Services
	Contact Us

ropinirol taj pharma api image

HOME >> API >> API List 3 >> Ropinirole >> Interaction

INTERACTION
Ropinirole CAS Registry Number 91374-21-9

Tell your doctor of any over-the-counter or prescription medication you may take, including: metoclopramide, medication for psychosis/anxiety/depression, other drugs used for Parkinson's, cimetidine, sleep medication, certain muscle relaxants, tranquilizers, narcotic pain relievers, anti-seizure drugs, certain antihistamines (e.g., diphenhydramine), ciprofloxacin. Do not start or stop any medicine without doctor or pharmacist approval.

L-dopa: Co-administration of carbidopa + L-dopa with ropinirole (2 mg 3 times daily) had no effect on the steady-state pharmacokinetics of ropinirole . Oral administration of Ropinirole 2 mg 3 times daily increased mean steady state Cmax of L-dopa by 20%, but its AUC was unaffected.

Digoxin: Co-administration of Ropinirole (2 mg 3 times daily) with digoxin (0.125 to 0.25 mg once daily) did not alter the steady-state pharmacokinetics of digoxin in 10 patients.

Theophylline: Administration of theophylline (300 mg twice daily, a substrate of CYP1A2) did not alter the steady-state pharmacokinetics of ropinirole (2 mg 3 times daily) in 12 patients with Parkinson's disease. Ropinirole (2 mg 3 times daily) did not alter the pharmacokinetics of theophylline (5 mg/kg IV) in 12 patients with Parkinson's disease.

Ciprofloxacin: Co-administration of ciprofloxacin (500 mg twice daily), an inhibitor of CYP1A2, with ropinirole (2 mg 3 times daily) increased ropinirole AUC by 84% on average and Cmax by 60%.

Estrogens: Population pharmacokinetic analysis revealed that estrogens (mainly ethinylestradiol: intake 0.6 to 3 mg over 4-month to 23-year period) reduced the oral clearance of ropinirole by 36% in 16 patients. Dosage adjustment may not be needed for Ropinirole in patients on estrogen therapy because patients must be carefully titrated with ropinirole to tolerance or adequate effect. However, if estrogen therapy is stopped or started during treatment with Ropinirole , then adjustment of the dose of Ropinirole may be required.

Dopamine Antagonists: Since ropinirole is a dopamine agonist, it is possible that dopamine antagonists such as neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide may diminish the effectiveness of Ropinirole . Patients with major psychotic disorders treated with neuroleptics should only be treated with dopamine agonists if the potential benefits outweigh the risks.

Information Associated with Product:

DRUG DESCRIPTION

DOSAGE

SIDE EFFECTS

PRECAUTIONS

INTERACTION >>

CONSUMER INFORMATION

PDF DOWNLOAD

WORD DOCUMENT


Product Enquiry	Product Quotation	Sample Request	Place Your Order

Taj Pharmaceuticals API Logo

Investor Relations Feedback Contact Worldwide Sitemap

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Limited products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.